GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C.
Hepatitis C virus (HCV) is a major cause of hepatitis worldwide, currently with 170 million chronic sufferers and future prognoses indicate this number to increase. HCV infects human liver cells and is the leading cause of liver cirrhosis and hepatocellular carcinoma and therefore, a major indication for liver transplantation. Unfortunately, the grafted liver is rapidly re-infected by the virus still present in the patient’s body and the disease re-develops. Although an interferon-based therapy is available, it is limited by side effects and resistance in many treated patients. A vaccine or other preventive approaches do not exist. Thus novel strategies for prevention and treatment are urgently needed.Due to the growing number of infected HCV patients resistant to current antiviral therapy, the total therapeutic market is expected to grow from a current 3-5 billion USD / year to 5-10 billion USD over the next 10 years.A major problem for the development of effective antiviral therapies lays in the biology of the virus. This is a so-called RNA virus which is prone to mutation during the formation of new viruses in the liver cells. Such mutations rapidly occur in patients and lead to new infective forms of the virus that become resistant to therapy. To infect the liver the virus requires so-called receptor proteins or entry factors, present on the surface of the liver cells, to which it attaches and thus gains entry to the cell, where it can start to divide and produce new viruses. New viruses can then infect neighbouring liver cells, leading to spread of the disease. The approach adopted by GENOVAC in Freiburg, Germany, and Inserm U748 in Strasbourg, France, is to generate antibodies that specifically bind to claudin-1 - a key HCV entry factor on the surface of the liver cells, thus blocking viral entry and infection of the liver cells. Unlike the mutating virus, these receptor proteins do not mutate but are used by all viral variants to gain cell entry. GENOVAC and Inserm have successfully generated monoclonal antibodies (i.e., cloned antibody-producing cells, which can be cultivated in cell culture indefinitely) of a given specificity for claudin-1 and two other HCV receptor proteins. All of these block infection of human liver cells in cell culture. Furthermore, they show broad blocking efficiency to all mutant variants of HCV including variants which escape the patient’s immune responses.The antibodies are now further developed to protect and treat HCV infection in patients. The antibodies could be applied to protect transplanted livers from chronic HCV infection. Investigations in animal models are underway to assess the possibility of treating chronically infected HCV patients.“Thus far, attempts to generate antibodies against the extracellular loop structures on the HCV receptor proteins have proven unsuccessful. By applying our unique genetic immunisation technology, we have now been successful in generating antibodies that not only recognise the native receptors on the surface of human liver cells, but actively block HCV entry.
GENOVAC GmbH Dr. Stefan LangWaltershofener Str. 17 79111 FreiburgDeutschlandTel.: +49-761-45636-0Fax: +49-761-45636-29 E-mail: firstname.lastname@example.org
Inserm U748, Université de StrasbourgProf. Thomas F. Baumert, MDNouvel Hôpital Civil3 rue Koeberlé67000 StrasbourgFrankreichTel.: +49-761-45636-0 Tel.: +33-3 68 85 37 03Fax: +49-761-45636-29 Fax: +33-3 68 85 37 50E-mail: Thomas.Baumert@unistra.fr